Thank you PYAR PYOU LIL BIRDCHIT TONY MORONTELO
“The issuance of this 9th U.S. patent in our global RPE portfolio represents yet another example of the leadership position we have established as pioneers in Regenerative Ophthalmology,” said Paul K. Wotton, Ph.D., President and Chief Executive Officer. “In particular, this new patent provides coverage for the manufacture of all RPE products from any pluripotent source by defining the basic universal markers of RPE essential for therapeutic use. We have recently received patent protection for the manufacture of human RPE cell products from pluripotent stem cell sources, including manufacture of formulation forms for use as therapeutic agents as well as the use of these RPE formulations for treating degenerative ophthalmic diseases, such as dry age-related macular degeneration (dry AMD) and Stargardt’s macular degeneration (SMD).”
Ocata Therapeutics, Inc. (NASDAQ:OCAT), a leader in the field of Regenerative Ophthalmology™, today announced that it continues to fortify the patent protection covering its retinal pigment epithelium (RPE) transplant technology for macular degeneration with the issuance by the United States Patent and Trademark Office (USPTO) of U.S. Patent No 9,080,150.
“Our preclinical research and patent estate firmly anchors our leading position in the development of this novel Restorative Immunology™ platform and gives Ocata the ability to partner the non-ophthalmic uses of its technology for the treatment of devastating autoimmune diseases.”
The results demonstrate promising potential therapeutic activity of a pluripotent stem cell-derived product for the treatment of autoimmune diseases such as lupus nephritis and Crohn's disease using Ocata’s proprietary Hemangio-derived Mesenchymal Cell (HMCTM) platform. This unique and proprietary HMC product has been shown to have highly potent immune-modulatory and anti-inflammatory activity and is potentially well-suited for commercial scale up with retention of therapeutic potency.
to be Reported at the International Congress on Systemic Lupus Erythematosus
Play into the strength of the market today with some good news? Not likely! He and TeddyBoy are still stuck in the phone booth trying to figure out how to open the door.
TNBH....restriking options is quite commonon stocks that have been beaten down for whatever reason. Lanza absolutely desrves to have his options repriced...